Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HINT1 | P49773 | 4/20 | 0.34 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.30 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.30 |
| ▸ | POLA1 | P09884 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18510954 | 1.00 | KDM4E (0.44) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 | |
| SCHEMBL25688968 | 0.97 | KDM4E (0.44) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 | |
| SCHEMBL21137315 | 0.96 | KDM4E (0.48) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 | |
| SCHEMBL18521378 | 0.96 | KDM4E (0.48) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 | |
| SCHEMBL18521410 | 0.96 | KDM4E (0.48) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 | |
| SCHEMBL21073963 | 0.96 | KDM4E (0.48) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 | |
| SCHEMBL5668128 | 0.93 | KDM4E (0.48) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 | |
| SCHEMBL26534160 | 0.91 | KDM4E (0.44) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 | |
| SCHEMBL26554447 | 0.90 | KDM4E (0.46) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 | |
| SCHEMBL20248707 | 0.90 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | KDM4E 4116/4885TAS1R3 453/4885TAS1R1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.